| Lisa Marie Dinubilo, PHARM D | |
|
5350 Shasta Dam Blvd, Shasta Lake, CA 96019-9402 | |
| (530) 275-1532 | |
| (530) 275-4199 |
| Full Name | Lisa Marie Dinubilo |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 5350 Shasta Dam Blvd, Shasta Lake, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497908552 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH61742 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lisa Marie Dinubilo, PHARM D 5350 Shasta Dam Blvd, Shasta Lake, CA 96019-9402 Ph: (530) 275-1532 | Lisa Marie Dinubilo, PHARM D 5350 Shasta Dam Blvd, Shasta Lake, CA 96019-9402 Ph: (530) 275-1532 |
News Archive
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
Florida Atlantic University's Charles E. Schmidt College of Medicine was recently awarded a $2.1 million, two-year contract by Otsuka America Pharmaceutical Inc. to conduct a study to examine the effectiveness of an injectable long-acting antipsychotic medication for schizophrenia and its impact on 30-day hospital readmission rates.
In a first-of-its-kind gathering at the New York Academy of Sciences, researchers from some of the world's leading universities and institutions convened to discuss the various applications of bioelectronic medicine, the cutting-edge field that uses technology to treat disease and injury.
The Pittsburgh Tissue Engineering Initiative, Inc. (PTEI) has been awarded a five-year grant from the National Institutes of Health (NIH) to develop a unique educational program focused on engaging middle school students, their teachers, and the general public in the wonders of tissue engineering and its applications.
Targeting vascular endothelial growth factor receptor-2 mediated signaling is an effective strategy against advanced gastric cancer, results from the REGARD trial demonstrate.
› Verified 3 days ago
Samantha Enzler, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5350 Shasta Dam Blvd, Shasta Lake, CA 96019 Phone: 530-275-1532 | |
John Meyer, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5350 Shasta Dam Blvd, Shasta Lake, CA 96019 Phone: 530-275-1532 | |
Thinh Tan Hoang, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5350 Shasta Dam Blvd, Shasta Lake, CA 96019 Phone: 530-275-1532 | |
Mr. Wayne Bann, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5350 Shasta Dam Blvd, Shasta Lake, CA 96019 Phone: 530-275-1532 Fax: 530-275-4199 | |
Bao Ying Huynh, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5350 Shasta Dam Blvd, Shasta Lake, CA 96019 Phone: 530-275-1532 | |
Dr. Natalie Codianne, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5350 Shasta Dam Blvd, Shasta Lake, CA 96019 Phone: 530-275-1532 |